Delisted from LSE in December 2022
ABC - Abcam plc
LSE
->
Healthcare
->
Biotechnology
Cambridge,
United Kingdom
Type: Equity
ABC price evolution
ABC
| (in millions $) | 30 Oct 2022 | 29 Jul 2022 | 30 Apr 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $20157.3 | $20317.96 | $19698.05 | $18691.12 |
| Inventory | $15556.39 | $15823.36 | $15514.85 | $16293.93 |
| Total current assets | $39589.76 | $39744.53 | $39409.74 | $39378.89 |
| Long term investments | ||||
| Property, plant & equipment | $2135 | $2104.76 | $2138.6 | $2129.7 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $56560.62 | $57173.63 | $57308.15 | $57577.56 |
| Current liabilities | ||||
| Accounts payable | $40192.89 | $39305.67 | $38210.62 | $38617.73 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $43477.96 | $43154.31 | $42797.58 | $41613.61 |
| Long term debt | $4632.36 | $4640.13 | $4646.71 | $6412.54 |
| Total noncurrent liabilities | $4646.71 | $6412.54 | ||
| Total debt | ||||
| Total liabilities | $56772.18 | $56949.33 | $56757.84 | $57336.02 |
| Shareholders' equity | ||||
| Retained earnings | $2977.65 | $2779.36 | $2469.71 | $2019.08 |
| Other shareholder equity | -$1830.97 | -$1421.3 | -$1005.82 | -$822.78 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 30 Dec 2021 | 30 Dec 2020 | 29 Jun 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $95.1 | $211.9 | $87.1 | |
| Short term investments | ||||
| Net receivables | $20157.3 | $52.6 | $40.4 | $44.1 |
| Inventory | $15556.39 | $58.2 | $42.9 | $36 |
| Total current assets | $39589.76 | $211.5 | $306.2 | $171.8 |
| Long term investments | $3.5 | $3.4 | $0.8 | |
| Property, plant & equipment | $2135 | $161.7 | $157.3 | $37.1 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $56560.62 | $986.1 | $818.6 | $446.7 |
| Current liabilities | ||||
| Accounts payable | $40192.89 | $12.9 | $13.8 | $7 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $43477.96 | $187.2 | $52 | $45.3 |
| Long term debt | $4632.36 | $6383.71 | $3618 | $4354 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $56772.18 | $330 | $189.5 | $61.9 |
| Shareholders' equity | ||||
| Retained earnings | $2977.65 | $289.6 | $271.7 | $260.1 |
| Other shareholder equity | -$1830.97 | $99.9 | $94.2 | $100.1 |
| Total shareholder equity | $656.1 | $629.1 | $384.8 | |
| (in millions $) | 29 Jul 2022 | 30 Apr 2022 | 31 Jan 2022 | 29 Oct 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $60064.6 | $57719.45 | $59628.81 | $58912.42 |
| Cost of revenue | ||||
| Gross Profit | $2042.99 | $2233.24 | $2060.36 | $1900.62 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $1384.27 | $1378.53 | $1346.04 | $1393.41 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $113.12 | $172.94 | $146.79 | $117.49 |
| Interest expense | -$61.76 | -$55.62 | -$48.07 | -$54.6 |
| Net income | ||||
| Net income | $406.96 | $548.01 | $449.11 | $437.7 |
| Income (for common shares) | ||||
| (in millions $) | 30 Dec 2021 | 30 Dec 2020 | 29 Jun 2019 | 29 Jun 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $315.4 | $295 | $259.9 | $233.2 |
| Cost of revenue | $87.7 | $85.8 | $76.7 | $70.2 |
| Gross Profit | $227.7 | $209.2 | $183.2 | $163 |
| Operating activities | ||||
| Research & development | $23.6 | $27.4 | $10.7 | $16 |
| Selling, general & administrative | $157.1 | $143.4 | $88.9 | $77.7 |
| Total operating expenses | $268.4 | $256.6 | $176.3 | $163.9 |
| Operating income | $47 | $38.4 | $83.6 | $69.3 |
| Income from continuing operations | ||||
| EBIT | $47 | $38.4 | $83.6 | $69.3 |
| Income tax expense | $0.3 | $5.6 | $11.4 | $6.9 |
| Interest expense | -$2.7 | -$3.8 | -$0.3 | -$0.3 |
| Net income | ||||
| Net income | $4.4 | $25.6 | $45 | $62.2 |
| Income (for common shares) | $4.4 | $25.6 | $45 | $62.2 |
| (in millions $) | 29 Jul 2022 | 30 Apr 2022 | 31 Jan 2022 | 29 Oct 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$193.71 | -$337.16 | -$143.12 | -$6141.58 |
| Financing activities | ||||
| Dividends paid | -$295.24 | -$197.92 | -$100.54 | -$366.65 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$1079.32 | -$384.59 | -$106.42 | $1952.85 |
| Effect of exchange rate | -$33.06 | -$5.05 | -$2.65 | -$3.73 |
| Change in cash and equivalents | $231.93 | $402.67 | $612.25 | -$1527.62 |
| (in millions $) | 30 Dec 2021 | 30 Dec 2020 | 29 Jun 2019 | 29 Jun 2018 |
|---|---|---|---|---|
| Net income | $4.4 | $25.6 | $45 | $62.2 |
| Operating activities | ||||
| Depreciation | $29.7 | $25 | $11.3 | $9.5 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $62.9 | $66.6 | $70.2 | $63.3 |
| Investing activities | ||||
| Capital expenditures | -$34.5 | -$23 | -$17.7 | -$16.4 |
| Investments | -$0.1 | -$0.1 | -$2.2 | -$2.2 |
| Total cash flows from investing | -$291.5 | -$44.4 | -$49.9 | -$37.7 |
| Financing activities | ||||
| Dividends paid | -$24.9 | -$22.1 | ||
| Sale and purchase of stock | ||||
| Net borrowings | $111.2 | -$221.6 | $100.2 | $100.2 |
| Total cash flows from financing | $111.4 | $30 | -$24.7 | -$20.6 |
| Effect of exchange rate | $0.4 | -$3 | $1.3 | $0.4 |
| Change in cash and equivalents | -$116.8 | $49.2 | -$3.1 | $5.4 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 206.20M |
| Revenue | $236.33B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $1.84B |
| Revenue Q/Q | 79.88K% |
| Revenue Y/Y | 79.28K% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $8.93 |
|---|---|
| ROA | 3.22% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.91 |
| Quick ratio | 0.55 |